High-grade B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for High-grade B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-01-29Clinical Trial Update: Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas [Phase 2]
Phase 2 study evaluating acalabrutinib plus lisocabtagene maraleucel (Liso-Cel) in refractory/relapsed aggressive B-cell lymphomas, includin…
-
CLINICAL_TRIALS research · 2026-01-29Clinical Trial Update: Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy [Phase 2]
A Phase 2 trial is evaluating whether vaccination with Prevnar 13 before and after CAR-T therapy can enhance cellular and humoral immunity i…
-
CLINICAL_TRIALS other · 2026-01-15Clinical Trial Update: Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL [Phase 1, Phase 2]
A Phase 1/2 study of E7777 for relapsed or refractory diffuse large B-cell lymphoma is suspended; no results are provided in this update.
-
CLINICAL_TRIALS other · 2026-01-08Clinical Trial Update: Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma [Phase 1]
Phase 1 clinical trial update on mosunetuzumab in combination with platinum-based salvage chemotherapy for relapsed/refractory aggressive B-…
-
CLINICAL_TRIALS research · 2025-12-29Clinical Trial Update: Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma
A recruiting clinical trial investigating how MYC aberrations and the tumor microenvironment affect diffuse large B-cell lymphoma and high-g…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-12-23Clinical Trial Update: A Compassionate Use (CU) Program of Odronextamab
Compassionate-use program update for odronextamab in relapsed or refractory B-cell lymphomas, including follicular lymphoma and diffuse larg…
-
CLINICAL_TRIALS research · 2025-12-22Clinical Trial Update: A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies [Phase 1]
This clinical trial update describes a Phase 1 study of GF-CART01, a CD20/CD19 CAR T cell therapy, evaluating safety and early activity in a…
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma [Phase 2]
Phase 2 clinical trial evaluating circulating tumor DNA (ctDNA) testing in people with diffuse large B-cell lymphoma and related high-grade …
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma [NA]
This clinical trial update describes the use of nanochip technology to monitor treatment response and detect relapse in participants with di…
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: Long-term Study to Evaluate Safety and Persistence of GF-CART01
This clinical trial update describes a long-term safety and persistence study of GF-CART01, with enrollment not yet starting.
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating a triple combination of tafasitamab, retifanlimab, and rituximab with standard therapy for diffuse lar…
-
CLINICAL_TRIALS trial_result · 2025-12-09Clinical Trial Update: Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T) [NA]
Clinical trial update on adaptive bridging radiotherapy for relapsed/refractory B-cell lymphomas prior to CAR-T therapy; the study status is…
-
CLINICAL_TRIALS research · 2025-11-26Clinical Trial Update: A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma [Phase 2]
Phase 2 clinical trial update for a glofitamab-based treatment in people with diffuse large B-cell lymphoma and high-grade B-cell lymphoma, …
-
CLINICAL_TRIALS research · 2025-11-14Clinical Trial Update: Emapalumab Prevention of CAR-T Cell Associated Toxicities [Phase 2]
A Phase 2 clinical trial update evaluating emapalumab for preventing CAR-T cell–related toxicities in patients with relapsed or refractory B…
-
CLINICAL_TRIALS research · 2025-11-06Clinical Trial Update: Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) [Phase 1]
Phase 1 clinical trial evaluating the combination of Rituximab and Tafasitamab with allogeneic NK cells in relapsed/refractory B-cell non-Ho…
-
CLINICAL_TRIALS research · 2025-10-20Clinical Trial Update: Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment [Phase 2]
This SWOG Cancer Research Network Phase 2 trial is evaluating adding drugs to standard therapy for large B-cell lymphoma that has returned o…
-
CLINICAL_TRIALS trial_result · 2025-10-08Clinical Trial Update: Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating the combination of acalabrutinib with anti-CD19 CAR T-cell therapy for various B-cell lymphomas, in…
-
CLINICAL_TRIALS trial_result · 2025-09-29Clinical Trial Update: Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) [Phase 2]
Phase 2 clinical trial assessing the combination of loncastuximab tesirine and epcoritamab in relapsed/refractory aggressive B-cell lymphoma…
-
CLINICAL_TRIALS trial_result · 2025-09-29Clinical Trial Update: Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma [Phase 2]
A Phase 2 clinical trial update notes Polatuzumab Vedotin in combination chemotherapy for previously untreated diffuse large B-cell lymphoma…
-
CLINICAL_TRIALS research · 2025-09-25Clinical Trial Update: Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma [Phase 1]
This Phase 1 trial evaluates low-dose radiation as bridging therapy for relapsed or refractory B-cell non-Hodgkin lymphomas, including DLBCL…
-
CLINICAL_TRIALS trial_result · 2025-08-11Clinical Trial Update: ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies [Phase 1]
Acepodia Biotech's Phase 1 trial of ACE1831 in adults with relapsed/refractory CD20-expressing B-cell malignancies is currently recruiting a…
-
CLINICAL_TRIALS trial_result · 2025-08-03Clinical Trial Update: Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies [Phase 1]
Phase 1 clinical trial update on genetically engineered CAR T cells (EGFRt/19-28z/IL-12) for relapsed or refractory CD19+ hematologic malign…
-
CLINICAL_TRIALS research · 2025-07-16Clinical Trial Update: A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10) [Phase 1]
Phase 1 LOTIS-10 study assessing the pharmacokinetics and safety of loncastuximab tesirine in relapsed or refractory diffuse large B-cell ly…
-
CLINICAL_TRIALS research · 2025-06-08Clinical Trial Update: Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma [Phase 2]
This clinical trial update describes a Phase 2 study at the University of Chicago assessing pembrolizumab plus chemotherapy for untreated B-…
-
CLINICAL_TRIALS other · 2025-05-16Clinical Trial Update: Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies [Phase 1]
Phase 1 clinical trial evaluating Genetically Engineered Anti-CD19/CD20/CD22 CAR T-cells for relapsed or refractory lymphoid malignancies; c…